Korro Bio Inc

Insight: Lynx1 Capital’s recent purchase of Korro Bio shares signals investor confidence in its RNA‑therapy platform and potential for a breakthrough as it moves toward phase‑II trials.

Insider buying surges at Korro Bio as NEA 17 backs its RNA‑therapeutic platform, signaling confidence in future clinical milestones and potential upside.

Insight: Korro Bio’s COO and top execs buy stock options—showing confidence in its RNA‑therapy pipeline and potential upside despite a volatile share price.